Dr Agarwal's Health (AGARWALEYE) | Financial Analysis & Statements
Dr Agarwal's Health Care Ltd Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
4.9B
Gross Profit
2.1B
43.48%
Operating Income
649.1M
13.32%
Net Income
380.6M
7.81%
EPS (Diluted)
₹0.95
Balance Sheet Metrics
Total Assets
36.7B
Total Liabilities
17.4B
Shareholders Equity
19.3B
Debt to Equity
0.91
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dr Agarwal's Health Income Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 17.0B | 8.4B | 10.2B | 7.0B |
| Cost of Goods Sold | 9.4B | 4.7B | 5.6B | 3.9B |
| Gross Profit | 7.7B | 3.6B | 4.6B | 3.1B |
| Gross Margin % | 45.1% | 43.3% | 45.1% | 44.5% |
| Operating Expenses | ||||
| Research & Development | - | - | - | - |
| Selling, General & Administrative | 1.1B | 849.0M | 609.4M | 390.4M |
| Other Operating Expenses | 1.4B | 1.4B | 895.7M | 643.4M |
| Total Operating Expenses | 2.5B | 2.3B | 1.5B | 1.0B |
| Operating Income | 2.5B | 917.5M | 1.5B | 960.2M |
| Operating Margin % | 14.6% | 11.0% | 15.1% | 13.8% |
| Non-Operating Items | ||||
| Interest Income | 92.3M | 80.2M | 48.5M | 32.3M |
| Interest Expense | 1.1B | 850.8M | 719.7M | 454.0M |
| Other Non-Operating Income | - | - | - | - |
| Pre-tax Income | 1.6B | 446.6M | 835.9M | 567.6M |
| Income Tax | 495.1M | 208.3M | -196.4M | 136.0M |
| Effective Tax Rate % | 31.0% | 46.6% | -23.5% | 24.0% |
| Net Income | 1.1B | 238.3M | 1.0B | 431.6M |
| Net Margin % | 6.5% | 2.9% | 10.2% | 6.2% |
| Key Metrics | ||||
| EBITDA | 4.9B | 3.1B | 2.8B | 2.0B |
| EPS (Basic) | ₹2.80 | ₹0.75 | ₹2.98 | - |
| EPS (Diluted) | ₹2.78 | ₹0.75 | ₹2.98 | - |
| Basic Shares Outstanding | 297645892 | 315879846 | 315879846 | - |
| Diluted Shares Outstanding | 297645892 | 315879846 | 315879846 | - |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Dr Agarwal's Health Balance Sheet From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Current Assets | ||||
| Cash & Equivalents | 1.0B | 1.1B | 1.3B | 996.2M |
| Short-term Investments | 4.1B | 4.7B | 336.6M | - |
| Accounts Receivable | 1.2B | 968.3M | 763.3M | 567.2M |
| Inventory | 802.7M | 519.0M | 360.4M | 329.2M |
| Other Current Assets | 185.3M | 121.1M | - | - |
| Total Current Assets | 7.9B | 7.6B | 3.1B | 2.3B |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 6.6B | 4.9B | 3.8B | 2.8B |
| Goodwill | 19.3B | 11.9B | 7.6B | 3.3B |
| Intangible Assets | 4.6B | 2.7B | 2.2B | 387.6M |
| Long-term Investments | 440.0M | 0 | 0 | 0 |
| Other Non-Current Assets | 248.6M | 104.7M | 170.0K | - |
| Total Non-Current Assets | 28.8B | 19.9B | 15.1B | 8.0B |
| Total Assets | 36.7B | 27.5B | 18.3B | 10.3B |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | 1.5B | 1.3B | 1.0B | 890.9M |
| Short-term Debt | 1.5B | 1.3B | 956.5M | 630.6M |
| Current Portion of Long-term Debt | - | - | - | - |
| Other Current Liabilities | 163.3M | 109.7M | 66.3M | 70.1M |
| Total Current Liabilities | 4.8B | 4.0B | 3.0B | 2.1B |
| Non-Current Liabilities | ||||
| Long-term Debt | 8.1B | 8.4B | 7.6B | 5.6B |
| Deferred Tax Liabilities | 69.6M | 15.1M | 24.5M | 12.8M |
| Other Non-Current Liabilities | - | - | - | - |
| Total Non-Current Liabilities | 12.7B | 9.7B | 8.6B | 5.9B |
| Total Liabilities | 17.4B | 13.7B | 11.7B | 7.9B |
| Equity | ||||
| Common Stock | 315.9M | 93.3M | 79.3M | 68.6M |
| Retained Earnings | -1.8B | -275.0M | -1.0B | -1.9B |
| Treasury Stock | - | - | - | - |
| Other Equity | - | - | - | - |
| Total Shareholders Equity | 19.3B | 13.8B | 6.6B | 2.3B |
| Key Metrics | ||||
| Total Debt | 9.6B | 9.7B | 8.6B | 6.2B |
| Working Capital | 3.2B | 3.6B | 88.6M | 214.8M |
Balance Sheet Composition
Dr Agarwal's Health Cash Flow Statement From 2022 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | 1.6B | 1.4B | 835.9M | 567.6M |
| Depreciation & Amortization | - | - | - | - |
| Stock-Based Compensation | 83.8M | 50.6M | 18.3M | 0 |
| Working Capital Changes | -1.3B | -356.0M | -301.8M | -332.8M |
| Operating Cash Flow | 1.4B | 2.0B | 1.2B | 632.1M |
| Investing Activities | ||||
| Capital Expenditures | 5.3M | 42.5M | 5.0M | 8.1M |
| Acquisitions | -5.2B | -2.9B | -3.2B | -797.1M |
| Investment Purchases | - | - | - | - |
| Investment Sales | - | - | - | - |
| Investing Cash Flow | -5.2B | -2.8B | -3.2B | -789.0M |
| Financing Activities | ||||
| Share Repurchases | - | - | - | - |
| Dividends Paid | -7.9M | -7.7M | -4.3M | -70.0K |
| Debt Issuance | 615.2M | 2.5B | 1.7B | 1.1B |
| Debt Repayment | -2.0B | -2.2B | -779.6M | -184.5M |
| Financing Cash Flow | 5.2B | 6.7B | 4.0B | 1.1B |
| Free Cash Flow | 394.3M | 1.1B | 753.0M | 937.4M |
| Net Change in Cash | 1.5B | 5.8B | 2.0B | 916.9M |
Cash Flow Trend
Dr Agarwal's Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
109.80
Forward P/E
77.92
Price to Book
7.17
Price to Sales
7.03
PEG Ratio
77.92
Profitability Ratios
Profit Margin
6.38%
Operating Margin
14.22%
Return on Equity
4.33%
Return on Assets
2.27%
Financial Health
Current Ratio
1.66
Debt to Equity
48.68
Per Share Data
EPS (TTM)
₹3.99
Book Value per Share
₹61.13
Revenue per Share
₹62.70
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AGARWALEYE | 138.9B | 109.80 | 7.17 | 4.33% | 6.38% | 48.68 |
| Poly Medicure | 151.0B | 43.53 | 5.17 | 12.24% | 19.51% | 8.17 |
| Tarsons Products | 11.0B | 55.45 | 1.81 | 4.72% | 4.91% | 63.18 |
| Laxmi Dental | 10.4B | 44.95 | 4.43 | 15.22% | 8.76% | 3.88 |
| Prevest Denpro | 5.4B | 27.33 | 4.69 | 17.20% | 27.78% | 0.00 |
| Shree Pacetronix | 532.1M | 20.75 | 3.24 | 5.44% | 12.10% | 32.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.




